Sakurai Kenichi, Fujisaki Shigeru, Nagashima Saki, Shibata Masahiko, Maeda Tetsuyo, Ueda Yuichi, Hara Yukiko, Enomoto Katsuhisa, Amano Sadao
Division of Breast and Endocrine Surgery, Dept. of Surgery, Nihon University School of Medicine.
Gan To Kagaku Ryoho. 2011 Nov;38(12):1927-9.
We evaluated a clinical significance of indoleamine 2,3-dioxygenase (IDO) in thyroid cancers. Operative specimens obtained from 20 patients with thyroid cancers were investigated by semi-quantitative RT-PCR with specific primers against IDO. The correlations among IDO expression, clinicopathologic factors and prognosis were studied. An expression of IDO was observed in 100% for both of the cancer specimens and the non-cancer specimens. The IDO expression of cancer specimens was significantly higher than the non-cancer specimens. The expression of IDO did not correlate to histologic classification, tumor size, lymphatic invasion, venous invasion and lymph nodes metastasis, but it was correlated to clinical stage. There was no correlation for survival rate after surgery between the high IDO level group and low IDO level group. The serum IDO levels of cancer patients were higher than that of a healthy volunteer measured by semi-quantitative RT- PCR and HPLC. It is suggested that the expression of IDO in thyroid cancer patients may play critical role for immunosuppression of those patients.
我们评估了吲哚胺2,3-双加氧酶（IDO）在甲状腺癌中的临床意义。采用针对IDO的特异性引物，通过半定量逆转录聚合酶链反应（RT-PCR）对20例甲状腺癌患者的手术标本进行研究。研究了IDO表达、临床病理因素与预后之间的相关性。癌组织标本和非癌组织标本中IDO的表达率均为100%。癌组织标本中IDO的表达显著高于非癌组织标本。IDO的表达与组织学分类、肿瘤大小、淋巴浸润、血管浸润及淋巴结转移无关，但与临床分期相关。IDO高水平组与低水平组术后生存率无相关性。通过半定量RT-PCR和高效液相色谱法（HPLC）检测发现，癌症患者血清IDO水平高于健康志愿者。提示甲状腺癌患者IDO的表达可能在这些患者的免疫抑制中起关键作用。
Zotero 插件